Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over

Garadacimab (Andembry, CSL Behring) is indicated for the 'routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older'.

The dosage schedule is available in the summary of product characteristics for garadacimab.

The list price of garadacimab for the subcutaneous injection is £20,625 for each prefilled pen (200 mg/1.2 ml).

The company has a commercial arrangement. This makes garadacimab available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, the Carbon Reduction Plan for UK carbon emissions is published on CSL Behring's webpage on sustainability.